ORIC Pharmaceuticals, Inc. (ORIC) Fundamental Analysis: Bull vs. Bear Case

ORIC

ORIC Pharmaceuticals, Inc.

Fundamental data last updated:November 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

VALUATION

P/E

-6.59

Market Cap ($M USD)

$874.72M

Forward P/E

-19.06

PEG

-0.29

PRICE TO SALES

0.00 PRICE TO BOOK

2.14 EV / EBITDA

-5.82

5-Year Average P/E

Free Cash Flow Yield

-12.73%

DCF Value

$0.35

Graham Number

N/A

Price to FCF

-7.85

EV to FCF

-7.35

Earnings Yield

-15.17%

FCF Yield

-12.73%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.28

Next Year EPS Growth Estimate

-$0.44

Next Year Revenue Growth Estimate

$259.28M

Return on Equity (ROE)

-35.33%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.03 Piotroski F-Score

2 Altman Z-Score

22.48 Return on Invested Capital (ROIC)

-35.78%

Current Ratio

16.33 Quick Ratio

16.33 Net Debt to EBITDA

0.40 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-1.06

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

The market’s valuation of ORIC Pharmaceuticals appears to be a stark misalignment with its intrinsic value. With a DCF value far below the snapshot price, the stock seems overpriced relative to its fundamental worth. The negative Forward P/E and Earnings Yield highlight a lack of profitability, yet the Altman Z-score of 23.27 suggests financial stability, indicating the company is not at immediate risk of distress. This paradox of safety amidst poor earnings performance creates a complex investment landscape, challenging the notion of growth without profitability. Investors must weigh these factors carefully, as the market may be pricing in future potential rather than current realities.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, ORIC Pharmaceuticals is inherently positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid adoption of tech innovations could enhance research efficiency and reduce time-to-market for new therapies. However, the company's current financial metrics suggest it must first stabilize its core operations to fully capitalize on these technological shifts.

The Bull Case

For the value-driven investor, ORIC's low Debt/Equity ratio of 0.03 and robust Current Ratio of 16.33 offer a fortress-like balance sheet, suggesting strong liquidity and minimal leverage risk. Despite a negative ROIC of -35.78%, the company's financial stability could provide a platform for future growth if management can harness its capital efficiently. The Piotroski F-Score of 2 indicates potential for improvement, and with institutional backing reflected in a "Buy" consensus, there is a speculative case for long-term upside if operational metrics improve.

The Bear Case

The bear case for ORIC Pharmaceuticals is compelling, with its negative EPS and a Forward P/E of -19.96 painting a grim picture of profitability. The Price/Book ratio of 2.25 suggests the stock is not cheap, especially when paired with a Price to FCF of -8.23, indicating poor cash flow generation. With no revenue per share and an FCF Yield of -12.16%, the company struggles to convert its operations into tangible shareholder value. The technical overextension, with the stock trading significantly below its 50-Day and 200-Day SMAs, further underscores the risk of a potential downturn.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$20.40

Institutional Ownership %

1-Year Beta

1.11 Insider Buying % (6 Mo)

Distance to 52-Week High

76.69%

Distance to 52-Week Low

14.44%

EARNINGS SURPRISE %

-9.68%

50-DAY SMA

$9.80

200-DAY SMA

$10.83

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.